These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Leu L; Mohassel L Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784 [TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Mayorga J; Richardson-Hardin C; Dicke KA Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466 [TBL] [Abstract][Full Text] [Related]
5. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide. Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771 [TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Douer D; Hu W; Giralt S; Lill M; DiPersio J Oncologist; 2003; 8(2):132-40. PubMed ID: 12697938 [TBL] [Abstract][Full Text] [Related]
8. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940 [TBL] [Abstract][Full Text] [Related]
9. Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Dombret H; Fenaux P; Soignet SL; Tallman MS Semin Hematol; 2002 Apr; 39(2 Suppl 1):8-13. PubMed ID: 12012316 [TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103 [TBL] [Abstract][Full Text] [Related]
11. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Iland HJ; Wei A; Seymour JF Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016 [TBL] [Abstract][Full Text] [Related]
12. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204 [TBL] [Abstract][Full Text] [Related]
15. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF; Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769 [TBL] [Abstract][Full Text] [Related]
16. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
17. New data with arsenic trioxide in leukemias and myelodysplastic syndromes. Sekeres MA Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365 [TBL] [Abstract][Full Text] [Related]
18. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. Bergstrom SK; Gillan E; Quinn JJ; Altman AJ J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675 [TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia: do we have a new front-line standard of treatment? Sanz MA; Iacoboni G; Montesinos P Curr Oncol Rep; 2013 Oct; 15(5):445-9. PubMed ID: 23990383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]